The study and its comparison
Two hundred seventy adults aged 20–40 at risk of weight gain were randomized to 10 grams daily of inulin-propionate ester or inulin for 12 months. The ester was intended to deliver more propionate to the colon. [1]
The adjusted weight-gain difference was not significant; its confidence interval included both directions. Adherence was incomplete, and both groups received a fermentable ingredient. [1]
What the finding establishes
The trial cannot determine either ingredient’s effect against no supplement. MRC/NIHR funding supported the research, and investigators disclosed a related patent and a commercialization company. The negative primary result should remain visible alongside earlier mechanistic or shorter-term findings. [1]
A hypothetical distinction
Imagine a promising mechanism is followed by a null year-long trial. The mechanism does not override the clinical comparison.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Increase in colonic PRopionate as a method of prEVENTing weight gain over 12 months in adults aged 20–40 years (iPREVENT): a multi-centre, double-blind, randomised, parallel-group trial - PMC
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.